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Abstract
Permanent cardiac pacing is nowadays a widespread method for the cure of conduction system
diseases, improving quality of life and often saving patients lives. In the twentieth century,
scientific efforts were focused on extending battery life, improving sensitivity and reliability,
minimizing the dimensions of the device and restoring atrio-ventricular synchrony and rate
response. However, there is more and more evidence for the deleterious influence of chronic
right ventricular pacing especially apical (RVA) pacing. DANISH, MOST, CTOPP and
DAVID trials have proven univocally that right ventricular pacing increases risk of heart
failure, atrial fibrillation and even mortality in patients with chronic heart failure. Such
knowledge inspires the quest for alternative pacing sites. Right ventricular outflow tract
(RVOT) became the most favourable non-apical pacing site. Since 1995 there have been
several reports concerning dual-site right ventricular pacing (DuVP: RVOT plus RVA pacing)
proving its beneficial clinical and hemodynamic outcome especially in the case of unsuccessful
left ventricle implantation for cardiac resynchronisation therapy (CRT). (Cardiol J 2007; 14:
224231)
Key words: dual-site right ventricular pacing, bifocal right ventricular pacing,
right ventricular outflow tract pacing, alternative ventricular pacing sites
Endocavitary, transvenous ventricular pacing,
which is presently the most widespread type of
cardiac pacing, has been commonly performed
since the nineteen-sixties. Scientific efforts were
focused on extending battery life, improving sen-
sitivity and reliability, minimizing the dimensions
of the device and restoring atrio-ventricular syn-
chrony and rate response. The consequences of
chronic right ventricular (RV) pacing, especially
apical pacing (RVA), were emphasized in the last
two decades.
Pacing hurts
The first successful transcutaneous human
myocardial stimulation was performed in 1952 [1].
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However, over 80 years have passed since the
first report on the harmful influence of chronic car-
diac pacing. In 1920, Koch published an experiment
which proved that right ventricular pacing caused
its asynchronous systole [2]. Five years later, Wig-
gers pointed out that epicardial ventricular stimu-
lation extended mechanical cardiac contraction time
and lowered systolic arterial pressure and its first
derivative (dP/dt) in the left ventricle compared
with atrial stimulation [3]. Many years passed, and
then in the early seventies attention was focused
on hemodynamic effects of ventricular pacing. Wig-
gers results were then confirmed by Boerth and
Covell on denervated dogs hearts [4]. Badke et al. [5]
have proven, also on dogs hearts, that every ven-
tricular stimulation causing improper interaction
between asynchronously contracting heart seg-
ments leads to a 20% decrease in systole effective-
ness. Coronary blood flow and oxygen consumption
in a paced ventricle is 30% lower in early-activated
segments and 30% higher in later activated ones.
This indirectly shows regional differences in work-
load [6, 7]. Permanent RV pacing lowers myocar-
dial perfusion especially in the apex and inferior wall
even without coronary arteries stenosis [8, 9]. Api-
cal pacing extends relaxation time, shortens left
ventricular filling period and causes ineffective in-
terventricular septum (IVS) systole, just like in the
presence of a left bundle branch block (LBBB); dur-
ing LV contraction, IVS remains relaxed and bows
to the blood flow which lowers heart stroke volume,
impairs mitral valve function and increases end-di-
astolic left ventricular volume [10].
A decade before the crucial DAVID trial, in
1993, Saxon et al. [11] showed that heart failure
mortality (HF) is increased three times in patients
with implanted cardioverter-defibrillator (ICD) and
heart failure. The DANISH study proved that atrial
pacing (compared to ventricular VVI pacing) was as-
sociated with lower mortality, incidence of heart
failure atrial fibrillation (AF) and thromboembolic
events [12]. These surprising results were sup-
posed to be due to asynchronous ventricular stim-
ulation with present sinus rhythm (SR). However,
the MOST study, comparing VVI with DDD pacing,
revealed that atrio-ventricular pacing (called phys-
iologic) did not lower AF incidence and HF hospi-
talisation. These end points were associated with
ventricular pacing percentage but not with pacing
mode. The probability of HF increased when ven-
tricular pacing share was greater than 40% while
atrial fibrillation incidence rose simultaneously [13].
The CTOPP study, similar to the DANISH
study, showed the superiority of DDD pacing over
VVI only in AF incidence. Overall mortality and
cardiovascular and thromboembolic mortality were
similar in both groups [14]. The nail in the coffin of
the safe ventricular pacing idea was the DAVID trial.
Over 500 patients with left ventricular ejection frac-
tion (LVEF) of 40% or less, with no need for per-
manent pacing and ICD indication, were randomised.
They were assigned to a backup pacing group (VVI
40/min) or dual-chamber pacing group (DDDR 70/
/min). Ventricular pacing percentage was below 3%
in the first group while about 60% in the other. So-
called physiologic pacing turned out to be harmful in
patients with heart failure  significantly increas-
ing heart failure hospitalisation and mortality [15].
According to the presented data, we are al-
lowed to state that permanent right ventricular pac-
ing causes adverse heart remodelling, decreases
contraction effectiveness, lowers coronary blood
flow, which finally leads to greater heart failure and
atrial fibrillation incidence, and even increases
mortality. Current knowledge concerning right ven-
tricular apical pacing was presented in detail in an
article by Kutarski [16].
Primum non nocere: RVOT pacing?
Although the first endocavitary lead was placed
(by Furman) in the right ventricular outflow tract
(RVOT) [17] its apex remains the most favourable
pacing site. Since the nineteen-nineties, there have
been more and more reports concerning RVOT
pacing. Karpavich et al. [18] in the canine heart in
1991 and de Cock et al. [19] in the human heart in
1992 showed the advantage of RVOT pacing over
apical pacing. Placing the lead in the outflow tract is
safe and feasible for an experienced physician [2022].
Giudici et al. [23] noticed a 20% cardiac output im-
provement right after relocating the pacing lead from
the apex to RVOT. This benefit continued during
follow up. Tse et al. [24] reported no change in ejec-
tion fraction during outflow tract pacing, while in the
case of apical pacing it decreased significantly. Moreo-
ver, an improve in cardiac output and left ventricle (LV)
filling conditions was proven by Baszak et al. [25] RVOT
pacing is advantageous, especially in heart failure pa-
tients, as shown by Kutarski et al. [26].
Primum non nocere: DuRV
Cardiac resynchronisation therapy (CRT) is
nowadays a reputable treatment in patients with
end stage chronic heart failure [2729]. Unfortu-
nately, 515% of attempts of CRT implantation are
unsuccessful due to coronary sinus/cardiac vein
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anatomy, high LV lead pacing threshold or phren-
ic nerve stimulation. Epicardial pacing is an alter-
native but requires a thoracotomy and general
anesthesia in patients in NYHA IIIIV functional
class. There are some reports indicating that dual-site
(also called bifocal) right ventricular pacing (DuRV =
= RVA + RVOT) improves hemodynamics and may
be useful especially in the case of left ventricular
lead implantation failure (Fig. 1, 2).
Figure 1. Dual-site right ventricular pacing: fluorosco-
pic view (A) and with bifocal right atrial pacing (B).
B
A
Figure 2. ECG (leads I, II, III) of three patients with apical (A),
outflow tract (B) and dual-site (C) pacing. Major influen-
ce of ventricular activation pattern derives from the
apical pacing which is due to retrograde ventricular
activation via Purkinje fibers.
RVAp RVOTp DuRVpA
RVAp RVOTp DuRVpC
RVAp RVOTp DuRVpB
227
Marcin Gu‡aj et al., Dual-site right ventricular pacing
www.cardiologyjournal.org
The first reports about DuRV were published
in 1997 when Buckingham et al.  [30] tested differ-
ent RV pacing sites and their influence on cardiac
output and QRS duration during EP studies in pa-
tients with intact left ventricle contractility. Dual-
site RV pacing significantly shortened QRS length
(duration) while cardiac output increase was insig-
nificantly higher than in the case of apical pacing.
Similar effects were reported by the same group of
scientists a year later but in patients with LV dys-
function. In both cases, results were obtained after
short, two-minute stimulation periods. Another
objection is that AV delay was arbitrarily set to
100 ms in order to avoid native conduction [31] and
fusion activation. Hochleitner et al. [32] observed
the advantageous influence of such a short AV pe-
riod in patients with drug resistant dilated cardio-
myopathy (DCM), but further investigations did not
confirm this concept.
In 2001, Pachon et al. [33] showed the advan-
tage of bifocal RV stimulation not only over apical
but also over RVOT pacing in a heterogeneous
group of DCM patients. 39 patients (Chagas disease,
ischemic heart disease, AV node ablation for tachy-
cardiomyopathy; mean NYHA class 3.1) had car-
diac pacemaker implantation with two leads in the
right ventricle (RVOT and RVA) and one in the right
atrium (excluding patients with AF). The ventricu-
lar leads were connected to conventional dual-
chamber pacemakers. First, an active fixation ven-
tricular lead was fixed in the high RV septum, the
other active or passive fixation lead was placed in
the apex. In AF patients, the septal and the apical
leads were connected to the atrial and ventricular
pacemaker connectors, respectively. In SR patients,
it was necessary to use a Y-connector. The cath-
ode of the ventricular channel was attached to the
tip of the septal lead, and the anode was connected
to the tip of the RV apex lead. This made it possi-
ble to pace bifocally, unifocally in RVA with unipo-
lar pacing and unifocally in RVOT with bipolar pac-
ing, when the pacing threshold was higher in RVA
than in RVOT. NYHA class, quality of life (accord-
ing to the Minnesota Living with Heart Failure
Questionnaire), QRS duration, echocardiographic
parameters (EF, cardiac output, mitral regurgita-
tion, LV filling parameters, LA area) and LV con-
traction synchrony using radionuclide angiocardi-
ography (in 6 patients) were evaluated to compare
different pacing modes. Bifocal right ventricular
pacing showed a statistically strong advantage over
both pacing modes in each parameter. Quality of life
(QOL) decreased after reprogramming to a conven-
tional pacing in eight patients forcing the investi-
gators to reprogram to DuRV pacing before the end
of the 30-day follow-up.
Meznes et al. [34] applied dual-site RV pacing
in 30 patients with Chagas disease HF (NYHA class
IIIIV) and atrial fibrillation. During the first
6 months of a 3-year follow-up, hemodynamic state
increased to III NYHA class, LVEF increased and
its end diastolic diameter decreased. However, af-
ter 612 months, all patients developed end stage
heart failure in IV NYHA class, echocardiographic
parameters were worse than before implantation
and Holter monitoring revealed more than a ten-
fold increase in severe ventricular arrhythmia per-
centage. Despite initial clinical improvement, the
overall mortality in the first 6 months was 43% and
during 3 years reached 76%, which corresponds
with a natural history of Chagas disease. Six out of
seven survivors had an ICD implanted. The mean
time to therapy was ca. seven months. The authors
do not try to explain the sudden collapse of signifi-
cant clinical improvement after six months. Proba-
bly, it is due to the biological course of Chagas dis-
ease and coincidence of AF, the influence of which
on cardiac resynchronisation therapy may be over-
whelming.
An interim report of an ongoing BRIGHT study
was presented during Cardiostim 2005. Forty pa-
tients with current CRT indications (NYHA class
III, wide QRS complex, LVEF below 35%) re-
ceived bifocal RV pacing systems implanted in one
of several Dutch centres. A six-minute walking
test, NYHA class, quality of life and LVEF were
evaluated after at least seven months follow-up.
Patients were randomised to backup VVI 40/min
pacing or DuRV atrio-ventricular pacing groups.
From the initial 40 implanted patients, only 26 of
them have recorded complete follow-up. In this
small group, the benefits were significant in favour
of bifocal pacing in LVEF, quality of life scores and
functional (NYHA) class. Moreover, five patients
could not tolerate spontaneous conduction after a
period of DuRV pacing. Unfortunately, until now
there exists only initial analysis [35] and techni-
cal aspects report [36] of this interesting but con-
troversial experiment.
Sodolski [37], during a temporal experiment,
assessed the hemodynamic response of different
right ventricular pacing sites (RVA vs. RVOT vs.
DuRV) using impedance cardiography. Cardiac out-
put, stroke volume, stroke index, cardiac index,
aortic velocity and acceleration index were at their
highest levels in the course of bifocal pacing, con-
versely to apical pacing. Kutarski et al. [38] proved
in a subsequent experiment that an improvement
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in systolic performance is observed especially in pa-
tients with impaired LV function.
Peichl et al. [39] examined electrical activation
sequence caused by pacing from various sites us-
ing the Carto system. Of 20 patients with NYHA
class III, 13 had CRT and 7 had DuRV pacemakers
implanted. Left ventricular activation time (LVAT),
interventricular delay (IVD) and QRS duration were
evaluated during native conduction and during pac-
ing from various sites (RVA, DuRV, BiV, LV).
DuRV pacing shortened LVAT only in comparison
with apical pacing. It did not decrease IVD or QRS
time. There was no significant improvement in func-
tional NYHA class in contrast to biventricular pac-
ing during a six-month follow-up. These investiga-
tions, although conducted on a very small and het-
erogeneous group, suggest restraint in terms of
treating DuRV pacing as an equal alternative to the
cardiac resynchronization therapy.
Stambler et al. [40] did not find a clear clinical
favour of bifocal pacing either. One hundred and
three patients in functional IIIII NYHA class with
chronic atrial fibrillation had dual-chamber pacemak-
ers with two RV leads (RVA and RVOT) implanted.
The aim of this study was to compare the influence
of different pacing sites on QOL, NYHA class,
echocardiographic parameters and QRS duration.
A group of 50 patients participated in a dual-site RV
substudy (with 31 ms RVOT/RVA delay) between
months 9 and 12 of follow-up. There was only a slight
improvement in NYHA class (comparing to RVOT),
besides there was no advantage of DuRV pacing.
The current is not all Case reports
The majority of designed dual-site RV pacing
publications are case reports describing individu-
als or small groups of patients after unsuccessful
LV lead implantation
Chudzik et al. [41, 42], in two reports including
8 and 9 patients with bifocal RV pacing (implanted
after unsuccessful CRT procedure), evaluated
functional conditions using a six-minute walk test
and NYHA classification and echocardiographic
measurements: LVEF, stroke volume (SV), systo-
lic (LVSD) and diastolic left ventricle diameter
(LVDD), cardiac output (CO), cardiac index (CI),
isovolumic contraction (ICT) and relaxation time
(IRT), interventricular mechanical delay (IVMD)
and ejection time (ET) and QRS duration. LVDD,
SV, IRT, ET and QRS times remained unchanged.
All other parameters and clinical markers improved
significantly during a three-month period of bifocal
pacing [41, 42].
Vlay [43] evaluated NYHA class in 22 patients
after unsuccessful CRT implantation followed by us-
ing a DuRV pacing type. This is how the functional
class advanced during a seven-month follow-up:
(during a seven-month follow-up, the NYHA class
improved as follows:) IV fi I (n = 6 patients),
IV fi II or III fi I (n = 10), IV fi III or III fi II (n = 3),
no change in 3 patients [43]. Malinowski and Jacob [44]
compared the clinical outcomes of CRT in patients
with chronic AF and SR. Six of forty-nine patients
had an additional lead implanted in RVOT after LV
lead placement failure. DuRV patients improved in
NYHA class and left ventricle ejection fraction, like-
wise CRT patients (results were statistically insig-
nificant due to the small number of DuRV patients).
QRS duration and mitral regurgitation (which was
initially small in the DuRV group) remained un-
changed. ODonnell et al. [45], in a similar work in
patients with sinus rhythm, showed that dual-site
RV pacing reduces heart failure hospitalisation time,
increases physical efficiency (NYHA class and six-
minute walk test), improves EF, LV contraction
synchrony and decreases mitral regurgitation and
QRS duration time comparably to CRT in twelve-
month follow-up. Like in the previous work, the
DuRV group was incomparably smaller  6 patients
of 44.
The next papers are single case reports. Vlay
and Kort [46] describe a 62-year old patient with
an ICD and severe heart failure in III NYHA class.
An attempt to implant a CRT system was unsuc-
cessful due to coronary sinus anatomy, so a bifocal
RV pacing system was applied. A clinical (II NYHA
class, QOL) and hemodynamic (impedance cardiog-
raphy) positive response and significant brain natri-
uretic peptide level decrease was observed within
the first week after the procedure. However, after
three weeks, all clinical parameters returned to in-
itial levels. It turned out that due to Twiddlers syn-
drome, the RVOT lead dislodged. After replace-
ment, the patient rapidly recovered, and after
12 months his NYHA class improved to I. The same
author reports two patients whose NYHA class low-
ered by one and two levels after applying bifocal
pacing but the follow-up period was very short
(8 weeks) [47]. Satish et al. [48] describe
a 46-year old patient with IV NYHA class heart fail-
ure, chronic AF and a permanent ventricular pace-
maker implanted seven years previously. He had
a CRT successfully implanted and improved to II
NYHA class. However, after 17 months, CRT was
replaced by DuVP due to a high LV threshold and
battery depletion. During 12 weeks of follow-up, the
patient remained in II NYHA class.
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Technical aspects
The implantation procedure was similar in most
of presented works. First, the active or passive fix-
ation ventricular lead was placed in the RV apex.
The other one was implanted in the high RV out-
flow tract, which was identified with fluoroscopy
(the active fixation lead was screwed in just below
the pulmonary trunk valve) and with ECG (positive
QRS complexes in II, III, aVF and negative or bi-
phasic in I). The atrial lead was usually placed in
the right atrial appendage. Pachon et al. [33] used
dual-chamber pacemakers with a Y-connector, as
described above. In other cases, CRT dedicated
pacemakers were used in patients with sinus
rhythm while in AF patients the RVOT and apical
leads were connected to the atrial and ventricular
connectors of a dual-chamber device, respectively.
In all cases, pacing and sensing parameters were
within acceptable ranges. Ventricular signal ampli-
tude was usually slightly lower in RVOT than in
RVA. An interventricular delay (i.e. RVOT-RVA
delay) was programmed, according to the limits of
the pacemaker, between 0 and 50 ms  the outflow
tract lead was paced as the first one. In ODonnells
report, it was optimised echocardiographically and
ranged between 4 and 36 ms. In dual-chamber pace-
makers the lowest delay (A-V delay) possible was
programmed (1031 ms). The atrio-ventricular delay
was set short to avoid native ventricular activation.
Summary
According to large, properly designed trials,
there is no doubt about the deleterious influence of
right ventricle apical pacing. Modern pacemakers
are equipped with algorithms minimizing ventricu-
lar pacing, but in patients with conduction system
disease there is no way to exclude it. Cardiac re-
synchronisation therapy, which eliminates, or at
least reduces, ventricular asynchrony, is a solution
for a narrow group of patients who may not have
typical indications for permanent pacing. There are
more and more enthusiasts of alternative pacing
sites. Until now, there have not been randomised
trials proving the advantage of dual-site ventricu-
lar pacing over apical or RV outflow tract pacing.
However, reports published to date, especially
works describing hemodynamic improvement after
CRT implantation failure or keeping positive re-
sponse after replacing CRT by DuRV pacing, let us
assume that bifocal pacing is hemodynamically
efficient (or at least less harmful than RVA pacing).
Obviously, the presented data do not entitle us to
treat DuRV as an equivalent to CRT, but it may be
a solution for patients who have pacing indications
and heart failure before the CRT stage and an
alternative when LV lead implantation fails.
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